Radiofrequency Ablation of Uterine Fibroids Clinical Coverage Criteria
Customize your policy alerts
Sign up for all fallon_community_health_plan_inc policy alerts
Know when fallon_community_health_plan_inc releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage criteria for laparoscopic and transcervical radiofrequency ablation of symptomatic uterine fibroids for Fallon Community Health Plan products, with specific MassHealth coverage provisions.
Radiofrequency ablation of uterine fibroids is covered for MassHealth members and, effective 06/01/2025, does not require prior authorization for specified CPT codes.
Fallon Health considers radiofrequency ablation experimental/investigational and not medically necessary for Fallon Health products (non-MassHealth).
Coverage Criteria and Rationale
Product-based coverage criteria
Coverage stance varies by product:
References MassHealth Transmittal Letter PHY-164 (June 2022).
Applies to Fallon Health Clinical Coverage Criteria unless superseded by Medicare or other regulatory/plan-specific requirements.
Evidence-based coverage rationale
Coverage rationale and clinical context for RFA procedures
Summarized from available clinical trials and meta‑analyses (Sonata and Acessa literature).
For Fallon Health products (non-MassHealth), radiofrequency ablation (RFA) of symptomatic uterine fibroids is considered experimental/investigational and not medically necessary. Requests for RFA for Fallon Health commercial products may be denied on this basis.
Many pivotal and registry studies of transcervical and laparoscopic RFA excluded people who desired future pregnancy; for example, the SONATA trial enrolled premenopausal women with fibroids 1–5 cm and listed desire for future pregnancy among key exclusion criteria. As a result, evidence on pregnancy and fertility outcomes is limited, and most published trials do not provide robust reproductive outcome data to guide treatment decisions for patients seeking future fertility.
Additionally, most studies of transcervical RFA were single-arm cohorts with limited long-term follow-up and few randomized comparisons, which restricts conclusions about comparative effectiveness and reproductive safety versus standard surgical options.
Restating policy: Fallon Health considers radiofrequency ablation experimental/investigational and not medically necessary for Fallon Health products (non-MassHealth). This stance applies unless coverage is governed by a different payer rule or applicable regulatory/plan mandates that override the Fallon Health clinical coverage position.
The evidence base notes limited data supporting RFA when the clinical intent is fertility preservation. Most trials limited treatable fibroids to approximately 1–5 cm and excluded women desiring pregnancy, and there are insufficient long-term comparative data to establish durability and reintervention rates versus standard surgical treatments. Reported post‑RFA hysterectomy and reintervention rates vary across studies, underscoring the need for additional long-term comparative trials to define the role of RFA for fertility-preserving care.
Procedure Codes and Typical Parameters
Prior Authorization, Documentation, and Billing Guidance
Prior authorization not required for MassHealth (CPT 58674, 58580)
For MassHealth members, ultrasound‑guided laparoscopic (CPT 58674) and transcervical (CPT 58580) radiofrequency ablation of symptomatic uterine fibroids do not require prior authorization for dates of service on or after 06/01/2025.
Obtain prior authorization when plan or Medicare/MassHealth rules require it
Obtain prior authorization when required by the member’s specific benefit plan or when dictated by applicable Medicare NCDs/LCDs or MassHealth requirements; coverage determinations follow Medicare NCDs/LCDs and MassHealth guidelines.
- If Medicare NCDs/LCDs or the member’s benefit plan require authorization, providers must request it.
- When Medicare criteria do not fully establish coverage, Fallon may apply internal criteria as described in policy instructions for use.
Document failed conservative/nonoperative treatments prior to transcervical RFA
MassHealth medical record documentation must include a summary of nonoperative/conservative treatments tried and unsuccessful prior to transcervical RFA.
- Documentation must state which nonoperative/conservative treatments were attempted and that they were unsuccessful in managing the patient’s condition.
- This summary is one of the required medical record elements for MassHealth medical necessity determinations.
Procedure and operative documentation — include approach, guidance, and indication
Provide clear operative and perioperative procedure details in the medical record: describe the approach (transcervical or ultrasound‑guided laparoscopic), intraoperative ultrasound guidance/monitoring, and device used; include indication and link to the member’s symptoms.
MassHealth — required medical record elements for RFA medical necessity
For MassHealth members, medical records must include: primary and secondary diagnosis names and ICD‑CM codes; the most recent medical evaluation with history and pelvic exam; results of relevant radiology studies; a summary of failed conservative treatments; and documentation of informed written consent including risk factors/comorbid conditions.
- 1) Primary diagnosis name(s) and ICD‑CM code(s). 2) Secondary diagnosis name(s) and ICD‑CM code(s) for comorbid conditions, if present. 3) Most recent medical evaluation including history and abdominal and pelvic exam. 4) Results of radiology studies (ultrasound, MRI, etc.) relevant to the procedure. 5) Summary of nonoperative/conservative treatments tried and unsuccessful. 6) Documentation of informed written consent noting risk factors/comorbid conditions.
Procedure coding and supporting clinical documentation (CPT coding must be documented)
Include procedure documentation that references the appropriate CPT code and supporting clinical records demonstrating symptomatic uterine fibroids and medical necessity consistent with applicable criteria.
Denial risk for Fallon Health (non‑MassHealth) members — RFA may be considered experimental
Requests for radiofrequency ablation for Fallon Health products (non‑MassHealth) may be denied because Fallon Health considers RFA experimental/investigational and not medically necessary for those products.
- This exclusion applies to Fallon Health products unless Medicare, MassHealth, or other governing rules dictate otherwise.
Coverage governed by Medicare, MassHealth, plan, and regulatory rules — follow controlling guidance
Coverage decisions may be governed by applicable Medicare NCDs/LCDs, MassHealth guidelines, the member’s benefit plan terms, or state/federal mandates; failure to conform to the controlling rules for the member’s product can lead to denial.
- For Medicare Advantage members, Fallon follows CMS NCDs/LCDs and applicable statutes/regulations when determining medical necessity.
- If a member’s benefit plan has provisions that conflict with this policy, the benefit plan provisions or applicable state/federal mandates take precedence.
Clinical Background and Device Information
Uterine fibroids (also called uterine myomas, fibromyomas, or leiomyomas) are common benign smooth muscle tumors of the uterus. Most fibroids are asymptomatic, but symptomatic fibroids can cause heavy menstrual bleeding, pelvic pressure or pain, and enlargement of the uterus. Definitive surgical options include hysterectomy and myomectomy; minimally invasive, uterus-preserving alternatives such as radiofrequency ablation have been developed and studied to reduce symptoms, decrease fibroid volume, and improve quality of life.
Definitions and Terminology
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.